Literature DB >> 1777552

Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis.

M A Daw1, P Deegan, E Leen, C O'Moráin.   

Abstract

Twenty-one patients with endoscopically confirmed duodenal ulceration, who had failed to heal with an H2-antagonist, were given omeprazole 20 mg o.m. for four weeks. Four antral biopsies from each patient were taken at endoscopy before, at the end of, and four weeks after treatment. Rapid urease test, culture, histopathology and transmission electron microscopy were carried out on these biopsies to determine the presence of Helicobacter pylori and improvement of gastritis. After four weeks of treatment, duodenal ulceration was healed in 16 (79%) of the patients; H. pylori was not detected by culture in 11 (50%) of the patients, and the associated gastritis improved in 12 (54%) patients. Four weeks after cessation of treatment the organism was cultured from antral biopsies of 18 (86%) of the patients and all of these had gastritis. Omeprazole treatment healed duodenal ulceration, improved gastritis temporarily, and suppressed but did not eradicate H. pylori.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1777552     DOI: 10.1111/j.1365-2036.1991.tb00047.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  16 in total

1.  Real-world Helicobacter pylori diagnosis in patients referred for esophagoduodenoscopy: The gap between guidelines and clinical practice.

Authors:  Dor Shirin; Shay Matalon; Benjamin Avidan; Efrat Broide; Haim Shirin
Journal:  United European Gastroenterol J       Date:  2016-01-08       Impact factor: 4.623

Review 2.  Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes.

Authors:  H X Xia; N J Talley; C T Keane; C A O'Morain
Journal:  Dig Dis Sci       Date:  1997-09       Impact factor: 3.199

Review 3.  Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.

Authors:  L B Barradell; D McTavish
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

4.  H. pylori-negative duodenal ulcer prevalence and causes in 774 patients.

Authors:  J P Gisbert; M Blanco; J M Mateos; L Fernández-Salazar; M Fernández-Bermejo; J Cantero; J M Pajares
Journal:  Dig Dis Sci       Date:  1999-11       Impact factor: 3.199

5.  Alternative method for transporting and storing gastric biopsy cultures of Helicobacter pylori.

Authors:  A Savio
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

6.  Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group.

Authors:  F Lanza; J Goff; D Silvers; J Winters; N Jhala; D Jennings; P Greski-Rose
Journal:  Dig Dis Sci       Date:  1997-12       Impact factor: 3.199

7.  Eradication of Helicobacter pylori with clarithromycin and omeprazole.

Authors:  R P Logan; P A Gummett; H D Schaufelberger; R R Greaves; G M Mendelson; M M Walker; P H Thomas; J H Baron; J J Misiewicz
Journal:  Gut       Date:  1994-03       Impact factor: 23.059

8.  Activity of omeprazole on Helicobacter pylori and relation to toxicity of strains.

Authors:  N Figura; D Armellini; M Bugnoli; P F Bayeli; C Gennari; J E Crabtree
Journal:  J Clin Pathol       Date:  1994-05       Impact factor: 3.411

Review 9.  Eradication of Helicobacter pylori: therapies and clinical implications.

Authors:  H J O'Connor
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

Review 10.  Acid suppression and gastric atrophy: sifting fact from fiction.

Authors:  R M Genta
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.